Brownstein Carrie 4
4 · Zentalis Pharmaceuticals, Inc. · Filed Oct 6, 2023
Insider Transaction Report
Form 4
Brownstein Carrie
Chief Medical Officer
Transactions
- Sale
Common Stock
2023-10-04$19.43/sh−8,906$173,012→ 107,407 total - Sale
Common Stock
2023-10-04$19.91/sh−1,722$34,285→ 105,685 total
Footnotes (3)
- [F1]The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units.
- [F2]The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $18.91 to $19.90. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $19.91 to $19.93. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.